What's in Sandoz Group AG's pipeline?

Sandoz Group AG has 47 drugs in our index: 14 marketed, 0 filed, 28 in Phase 3, 0 in Phase 2, 4 in Phase 1.

Which companies overlap with Sandoz Group AG's portfolio?

Top competitors by shared drug class: Amgen, Celltrion, GlaxoSmithKline, Pfizer, Hoffmann-La Roche.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sandoz.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Sandoz Group AG — Portfolio Competitive Intelligence Brief

Sandoz Group AG (SDZ) pipeline: 14 marketed, 0 filed, 28 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

SDZ (SIX) 14 marketed 0 filed 28 Phase 3 0 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
HX575 recombinant human erythropoietin alfa	HX575 recombinant human erythropoietin alfa	marketed
Duragesic	Duragesic	marketed			Other
ENZEEVU	AFLIBERCEPT-ABZV	marketed			Other
Generic tacrolimus	Generic tacrolimus	marketed
Opana	Opana	marketed			Other
ZIEXTENZO	PEGFILGRASTIM-BMEZ	marketed	Leukocyte Growth Factor [EPC]		Other
HYRIMOZ	ADALIMUMAB-ADAZ	marketed	Tumor Necrosis Factor Blocker [EPC]		Other
JUBBONTI	DENOSUMAB-BBDZ	marketed	RANK Ligand Inhibitor [EPC]		Other
Omnitrope	Omnitrope	marketed		Growth hormone receptor	Other
CIMERLI	RANIBIZUMAB-EQRN	marketed	Vascular Endothelial Growth Factor Inhibitor [EPC]		Other
TYRUKO	NATALIZUMAB-SZTN	marketed	Integrin Receptor Antagonist [EPC]		Other
MabThera	MabThera	marketed	CD20-targeting monoclonal antibody	CD20	Oncology, Immunology

Therapeutic area mix

Other · 10
Immunology · 6
Oncology · 5
Hematology/Oncology · 3
Hematology · 2
Oncology, Immunology · 2
Hematology / Oncology · 2
Respiratory/Otolaryngology · 1
Cardiovascular · 1
Unknown · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Amgen · 9 shared drug classes
Celltrion · 6 shared drug classes
GlaxoSmithKline · 6 shared drug classes
Pfizer · 5 shared drug classes
Hoffmann-La Roche · 4 shared drug classes
Assistance Publique - Hôpitaux de Paris · 4 shared drug classes
· 3 shared drug classes
Ahn-Gook Pharmaceuticals Co.,Ltd · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Sandoz Group AG:

Cite this brief

Drug Landscape (2026). Sandoz Group AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sandoz. Accessed 2026-05-13.